FDA Regulation of AI-Enabled Medical Devices — Doctor-Like Assessment and Evidence Gaps (Updated 2026)
OVERVIEWUPDATE ADDS: The FDA is considering a physician-inspired evaluation framework for generative AI medical devices. Forbes reports regulatory disagreement between FDA and states about who should regulate clinical AI. The Bipartisan Policy Center comments on FDA's generative AI framework. Multiple governance frameworks are emerging from Nature (AEGIS) and HCI Innovation Group emphasizing patient safety. The FDA's approach emphasizes competency-based assessment, but this contrasts with state-level restrictions (Pennsylvania, California) that take more prescriptive approaches. Regulatory fragmentation is creating compliance complexity. The FDA's pre-authorization pathway (TEMPO Pilot) differs from state restrictions on AI mental health tools and insurance AI oversight. Health systems and vendors must navigate this patchwork of federal and state requirements. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.